Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) Receives $37.00 Average Target Price from Brokerages

Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) has received a consensus recommendation of “Buy” from the twelve research firms that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $37.00.

A number of brokerages have weighed in on RHHBY. Deutsche Bank upgraded Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a research note on Thursday, June 20th. Liberum Capital lowered Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a research note on Thursday, June 20th. UBS Group upgraded Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a research note on Friday, July 26th. Finally, Zacks Investment Research upgraded Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research note on Tuesday, July 9th.

OTCMKTS RHHBY traded up $0.14 during trading on Friday, reaching $34.70. The company’s stock had a trading volume of 1,652,045 shares, compared to its average volume of 1,166,810. The stock has a market capitalization of $237.12 billion, a PE ratio of 14.96, a P/E/G ratio of 2.28 and a beta of 0.48. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.40 and a quick ratio of 1.11. The firm has a fifty day moving average of $34.31 and a 200 day moving average of $33.89. Roche Holdings AG Basel has a one year low of $25.10 and a one year high of $35.90.

A number of hedge funds and other institutional investors have recently made changes to their positions in RHHBY. Quadrant Capital Group LLC boosted its holdings in shares of Roche Holdings AG Basel by 40.1% in the 1st quarter. Quadrant Capital Group LLC now owns 48,835 shares of the company’s stock worth $1,662,000 after purchasing an additional 13,984 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Roche Holdings AG Basel by 4.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 5,407,314 shares of the company’s stock valued at $185,958,000 after acquiring an additional 217,308 shares during the period. Trust Co. of Vermont boosted its holdings in Roche Holdings AG Basel by 1.6% during the 1st quarter. Trust Co. of Vermont now owns 32,062 shares of the company’s stock valued at $1,104,000 after acquiring an additional 505 shares during the period. Dearborn Partners LLC boosted its holdings in Roche Holdings AG Basel by 11.9% during the 1st quarter. Dearborn Partners LLC now owns 9,339 shares of the company’s stock valued at $321,000 after acquiring an additional 992 shares during the period. Finally, Ferguson Wellman Capital Management Inc. boosted its holdings in Roche Holdings AG Basel by 3.3% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 339,477 shares of the company’s stock valued at $11,675,000 after acquiring an additional 10,701 shares during the period. Institutional investors and hedge funds own 0.31% of the company’s stock.

About Roche Holdings AG Basel

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Recommended Story: What Factors Can Affect Return on Equity?

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.